Latest News
Dec 17, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Delayed-Release Tablets USP, 1.2 g, a generic version of Shire's Lialda® Delayed-Release...

Dec 17, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Rectal Suppository, 1000 mg, the first generic version of Allergan's Canasa® Rectal...

Dec 13, 2018

Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and found all claims of...

Dec 4, 2018

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing...

Dec 4, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Lansoprazole Delayed-Release (DR) Orally Disintegrating Tablets (ODT), 15 mg and 30 mg, a generic version...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected